Market Eyes LiveBaxter International Inc. (BAX) Stock Rating & Analysis
MELANY's data-driven read on Baxter International Inc. · Surgical & Medical Instruments & Apparatus.
Baxter supplies a range of medical products and equipment to providers. Its legacy operations sell injectable therapies for care settings, including IV pumps, administrative sets, and solutions, plus nutritional products and surgical sealants and hemostatic agents. Its late-2021 Hillrom acquisition added hospital beds, operating room equipment, and patient monitoring tools. Baxter sold its kidney care tools in early 2025.
Why BAX scores 61/100
MELANY scores Baxter International Inc. 61/100 by weighing eight factors. Here is how BAX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- FCF yield 7.3%
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +10.7% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +16%
What Wall Street price targets and revisions are signalling.
- Institutional net buying +4.3%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for BAX
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Baxter International Inc. sits in the Healthcare sector theme, which MELANY currently rates 57/100 for strength. Theme strength feeds BAX's momentum and catalyst factors above.
BAX trade plan (members only)
MELANY has a full position plan for Baxter International Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates BAX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Baxter International Inc.'s 61/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BAX
Is Baxter International Inc. (BAX) a buy?
As of 2026-08-25, MELANY rated Baxter International Inc. Very Promising with a composite score of 61/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Baxter International Inc.'s MELANY score?
Baxter International Inc. (BAX) has a MELANY composite score of 61/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the BAX stock rating calculated?
MELANY scores BAX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Baxter International Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Baxter International Inc. (BAX) Very Promising with a composite of 61/100 as of 2026-08-25. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BAX stock price forecast?
MELANY does not publish price targets or forecasts for BAX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 61/100 across eight factors for Baxter International Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BAX stock overvalued or undervalued?
MELANY's valuation factor currently reads 68/100 for Baxter International Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BAX's read.
What price should I buy BAX at?
Rather than chasing the current price, MELANY computes a smart entry zone for BAX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying BAX stock?
The top risks MELANY currently flags for Baxter International Inc.: No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Baxter International Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 35/100 for Baxter International Inc., and earnings track record, at 94/100. The 61/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BAX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 80/100 for BAX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BAX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-25. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BAX continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
BAX's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.